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Aims: Dietary nitrate from sources such as beetroot juice lowers blood pressure
(BP) via the nitrate–nitrite–nitric oxide (NO) pathway. However, NO and nitrite are
inactivated via reoxidation to nitrate, potentially limiting their activity. Cytochrome
P450-3A4 inhibition with troleandomycin prevents nitrite re-oxidation to nitrate
in rodent liver. Grapefruit juice contains the CYP3A4 inhibitor furanocoumarin.
We therefore hypothesized that grapefruit juice would enhance BP-lowering with
beetroot juice by maintaining circulating [nitrite].
Methods: We performed a randomized, placebo-controlled, 7-hour crossover study
in 11 healthy volunteers, attending on 3 occasions, receiving: a 70-mL shot of active
beetroot juice (Beet-It) and either (i) 250 mL grapefruit juice (Active Beet+GFJ), or
(ii) 250 mL water (Buxton, Active Beet+H2O); or (iii) Placebo Beet+GFJ.
Results: The addition of grapefruit juice to active beetroot juice lowered systolic
BP (SBP): Active Beet+GFJ vs Active Beet+H2O (P = .02), and pulse pressure,
PP (P = .0003). Peak mean differences in SBP and PP were seen at T = 5 hours:
−3.3 mmHg (95% confidence interval [CI] −6.43 to −0.15) and at T = 2.5 hours:
−4.2 mmHg (95% CI −0.3 to −8.2), respectively. Contrary to the hypothesis,
plasma [nitrite] was lower with Active Beet+GFJ vs Active Beet+H2O (P = .006),
as was salivary nitrite production (P = .002) and saliva volume (−0.34 mL/min
[95% CI −0.05 to −0.68]). The taste score of Beet+GFJ was 1.4/10 points higher
than Beet+H2O (P = .03).
Conclusion: Grapefruit juice enhanced beetroot juice's effect on lowering SBP
and PP despite decreasing plasma [nitrite]. Besides suggesting more complex
mechanisms, there is potential for maximising the clinical benefit of dietary nitrate
and targeting isolated systolic hypertension.
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1 | INTRODUCTION
Dietary inorganic nitrate (NO3
−) is found in beetroot and green leafy
vegetables. Beetroot juice has been shown to produce beneficial
cardiovascular effects,1 decreasing blood pressure (BP) in both healthy
volunteers2 and in patients with hypertension.3–5 Furthermore,
independent of peripheral BP, in hypertensive patients with or at risk
of diabetes mellitus, chronic treatment with beetroot juice over
6 months results in beneficial changes in cardiac chamber volume.6
Dietary nitrate also has additional benefits on platelets, endothelial
function and mitochondrial efficiency.7,8
Much of the recent focus on the nitrate-nitrite- nitric oxide (NO)
pathway has been on the mechanisms of bioactivation: nitrate
reduction to nitrite (i.e. via the enterosalivary circulation and lingual
bacterial nitrate reductases9,10), and nitrite reduction to NO (e.g. by
deoxyhaemoglobin11). However, the redox nature of these metabolic
processes permits re-oxidation of NO back to nitrite and then nitrate.
Indeed, before the enterosalivary pathway was characterised, nitrate
and nitrite were thought to be merely biologically inert by-products of
NO oxidation, rather than key components of an important NO
synthase-independent mechanism of NO production.
The cytochrome P450 (CYP) enzymes, particularly CYP3A,
present in gut enterocytes and the liver12 which play a major role in
drug metabolism, may also be involved in nitrite oxidation. Using
troleandomycin to inhibit CYP3A4, Curtis et al. recently demonstrated
inhibition of nitrite re-oxidation back to nitrate in rat liver
homogenates.13 Grapefruit juice is recognised as interacting with
many drugs via inhibition of CYP3A4,14 attributed to furanocoumarins
in the juice, particularly 60 ,70-dihydroxybergamottin.15 Thus, it is
plausible that the co-ingestion of grapefruit juice with beetroot
juice would decrease CYP3A4-mediated oxidation of nitrite to nitrate,
resulting in an increased plasma nitrite concentration.
We hypothesised that grapefruit juice, when co-ingested
with beetroot juice, would potentiate beetroot juice's BP-lowering
effect, via increased plasma nitrite concentration due to furanocoumarin-
mediated CYP3A4 inhibition of nitrite oxidation.
2 | METHODS
2.1 | Approvals
Ethical approval for this study was obtained from the South East
London Research Ethics Committee (REC; 10/H0802/52). Written
informed consent was obtained from all volunteers prior to commencing
any protocol-related procedures.
2.2 | Participants
Participants were healthy volunteers aged 18–45 years, with
normal BP (systolic BP [SBP] 90–140 mmHg and diastolic BP
[DBP] <90 mmHg), a body mass index (BMI) of 18–40 kg/m2 and
without any recent illness or regular systemic medication (other than
oral contraceptive pill).
2.3 | Study design
A 3-visit randomised (for the 2 active beetroot juice visits),
single-blind (with respect to active vs placebo beetroot juice),
placebo-controlled crossover intervention design was used. The
3 different visits involved the consumption of either:
• Active beetroot juice (nitrate-containing: 0.4 g) and golden
grapefruit juice (Active Beet+GFJ) i.e. 70 mL of nitrate-containing
beetroot juice shot (Beet-It James White Drinks, UK) with 250 mL
of grapefruit juice (Golden Grapefruit Juice, Tropicana UK Ltd, UK).
• Active beetroot juice and water (Active Beet+H2O) i.e. 70 mL of
nitrate-containing beetroot juice shot + 250 mL of low-nitrate
water (<0.1 mg/L, Buxton Mineral Water, UK).
• Placebo beetroot juice (nitrate-depleted) and grapefruit juice
(Placebo Beet+GFJ) i.e. 70 mL of nitrate-depleted beetroot juice
shot (James White Drinks, UK) + 250 mL of grapefruit juice. The
placebo beetroot juice is identical in appearance, taste, and smell
to the active beetroot juice. This visit was performed once the
volunteer had completed the 2 active beetroot juice visits.
Each of the visits lasted 7 hours. For the duration of the visit,
participants sat in an examination chair with their feet resting on a
stool (to avoid changes in posture affecting plasma [nitrite]).16 Blood
pressure was measured in triplicate every 15 minutes from 1 hour
(T = −1) before ingestion of the juice intervention at (T = 0) and until
6 hours postingestion. The BP for an individual at a given time point
was taken as the average of the 3 (triplicate) readings. The BP
readings from timepoints T = −1 to T = 0 were averaged to produce a
What is already known about this subject
• Dietary nitrate (e.g. beetroot juice) lowers blood pressure
via the nitrate–nitrite– nitric oxide pathway.
• Cytochrome P450-3A4 inhibition with troleandomycin
prevents nitrite re-oxidation to nitrate in rodent liver.
What this study adds
• Grapefruit juice potentiated the systolic blood pressure-
lowering effect of beetroot juice, despite decreasing
plasma [nitrite] and salivary nitrite production.
• The haemodynamic mechanisms are unclear but may
involve a synergistic dynamic effect and/or the production
of nitric oxide species other than nitrite.
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baseline reading. Blood pressure measurements were taken according
to guidelines, using an automated BP monitor (Intellisense 705IT,
Omron, UK). To avoid the action of BP recording interfering with the
measurement of plasma [nitrate]/[nitrite],17,18 BP recordings were taken
from the arm contralateral to that from which blood samples were
taken. Recordings of heart rate were taken alongside BP recordings.
To ensure participants remained hydrated during the study visit,
we adopted an optimised hydration protocol whereby at every hour
following the juice intervention, participants consumed 250 mL of
low-nitrate water (<0.1 mg/L, Buxton Mineral Water, UK). Participants
were given 2 slices of toasted Hovis wholemeal thick brown bread
just after T = 3 h.
Volunteers were asked to rate the taste of each intervention
by giving it a score of between 1 and 10 (disgusting–delicious),
immediately after drinking the intervention.
2.4 | Sample collection
Blood and saliva samples were taken immediately prior to ingestion of
each of the juice interventions, then at 30-minute intervals for the
first 3 hours, and hourly for the final 3 hours. At time points where BP
and blood samples were taken, BP recordings were taken prior to
blood sampling. Urine samples were collected every hour, and the pH
and volume recorded. A urine dipstick was performed upon collection
of the first urine sample to exclude the possibility of high nitrite
concentrations due to the presence of a urinary tract infection.
At each blood draw, 6 mL of venous blood was drawn into a
chilled syringe then transferred to a chilled green lithium heparin tube
(Vacutainer, BD). Samples were immediately centrifuged at 4C and
2000 g for 5 minutes (MIKRO 220R, Hettich, Germany), after which
plasma was collected.
Prior to collection of saliva, volunteers were asked to avoid
swallowing saliva for 2 minutes. They were then asked to drool
all saliva into a collecting tube. The volume of saliva collected
was recorded.
All plasma, saliva and urine samples were divided into 2 chilled
2-mL tubes and stored at −80C.
2.5 | Sample analysis
Plasma and saliva samples were analysed for nitrate and nitrite
concentrations using chemiluminescence, as described previously.19 The
quantification of nitrate and nitrite in plasma and saliva was performed
by an investigator who was blinded to the treatment allocation.
2.6 | Data analysis
In this pilot study, data was analysed using GraphPad Prism 8.0
(GraphPad Software Inc.). All data are expressed as mean ± standard
error of the mean unless otherwise stated (e.g. non-parametric
statistics [median ± interquartile range] for non-normally distributed
data). Data were compared by 2-way ANOVA and/or 1-way ANOVA
as appropriate, with Fisher's LSD post-test. P < .05 was considered
statistically significant.
3 | RESULTS
A total of 11 volunteers were enrolled in the study (of 11 potential
volunteers screened, all 11 were eligible and randomised). Volunteer
baseline demographics for the 11 participants are shown in Table 1.
Of the 11 volunteers, 9 completed all 3 visits (the other 2 volunteers
did not attend the Placebo Beet+GFJ visit). There were no adverse
events attributed to study participation.
3.1 | Plasma
The addition of grapefruit juice to active beetroot juice (Active Beet
+GFJ) had no effect on plasma [nitrate] compared to active beetroot
juice with water (Active Beet+H2O); P = .38 (Figure 1A). Plasma
nitrate was not measured for the Placebo Beet+GFJ intervention.
As anticipated, both Active Beet+GFJ and Active Beet+H2O
significantly increased plasma [nitrite] compared to Placebo Beet+GFJ
(both P < .0001). Comparison between the 2 active beet interventions
found that the addition of grapefruit juice decreased mean plasma
[nitrite] by 14%; P = .006 (Figure 1B).
3.2 | Saliva
Grapefruit juice decreased nitrate secretion into the mouth (measured
as total salivary nitrate and nitrite production), which was lower in
Active Beet+GFJ than Active Beet+H2O (P = .02), with the peak
difference occurring at T = 1.5 h: −437 μmol/h (95% confidence
interval [CI] −844 to −30); see Figure 2A. Salivary nitrite production
TABLE 1 Clinical parameters of participants, taken at time of
screening.
Parameter Value
Number of participants (n) 11
Sex (n male) 8
Age (y) 23 ± 4
Weight (kg) 60.9 ± 9.8
BMI (kg/m2) 21.3 ± 1.9
HR (beats/min) 80 ± 14
SBP (mmHg) 122 ± 8
DBP (mmHg) 75 ± 8
Data are mean ± standard deviation
BMI, body mass index; HR, heart rate; SBP, systolic blood pressure; DBP,
diastolic blood pressure
O'GALLAGHER ET AL. 3
was markedly decreased by grapefruit juice: i.e. lower with Active
Beet+GFJ than Active Beet+H2O (P = .002); see Figure 2B. Salivary
[nitrate]:[nitrite] was higher with Active Beet+GFJ vs Active Beet
+H2O (P = .01), with the peak difference occurring at T = 0.5 h: +7.4
(95% CI +1.5 to +13.3); see Figure 2C.
Dietary nitrate (Active Beet+H2O) increased salivary flow from
baseline, P = .02 overall, and by 0.38 mL/min at 4 h (95% CI 0.16 to
0.61); see Figure 3A. Whilst grapefruit juice (Placebo Beet+GFJ) did
not significantly decrease salivary flow relative to baseline, P = .7,
grapefruit juice appeared to exert an astringent effect compared to
Active Beet+H2O: salivary volume was decreased with Placebo Beet
+GFJ (P < .0001) and Active Beet+GFJ (P = .04) with the peak
difference occurring at T = 4 h: −0.34 mL/min (95% CI −0.05 to
−0.68); see Figure 3A.
Grapefruit juice significantly increased the salivary pH when
combined with dietary nitrate (P = .005) for Active Beet+GFJ vs Active
Beet+H2O (Figure 3B). Dietary nitrate also increased salivary pH
compared to grapefruit juice: Active Beet+H2O vs Placebo Beet+GFJ
(P < .0001) with the peak difference occurring at T = 3 h: ΔpH 0.37
(95% CI 0.16 to 0.58). Grapefruit juice without dietary nitrate resulted
in decreased salivary pH: Placebo Beet+GFJ vs Active Beet+GFJ
(P < .0001) with the peak difference occurring at T = 3 h: ΔpH 0.53
(95% CI 0.26 to 0.80).
3.3 | Blood pressure
Baseline BP data are presented inTable 2.
The addition of grapefruit juice to active beetroot juice
resulted in a lower SBP: Active Beet+GFJ vs Active Beet+H2O
(P = .02), with the peak mean difference in SBP seen at T = 5 hours:
−3.3 mmHg (95% CI −6.43 to −0.15); see Figure 4A. As expected,
active nitrate-containing beetroot juice (Active Beet+GFJ) also
lowered SBP vs Placebo Beet+GFJ (P = .0005). However, no
difference in SBP was seen between Active Beet+H2O and
Placebo Beet+GFJ. Relative to baseline, SBP was decreased by
the active nitrate-containing beetroot juice combinations: Active
Beet+GFJ (P = .02) and Active Beet+H2O (P < .01) but not by
Placebo+GFJ (P = .09).
In contrast to SBP, grapefruit juice tended to increase DBP,
i.e. Active Beet+GFJ vs Active Beet+H2O (P = .04); see Figure 4B.
Moreover, Placebo Beet+GFJ resulted in a significant decrease
in DBP vs Active Beet+GFJ (P = .002) but not Active Beet+H2O
(P = .1). Relative to baseline, DBP was not decreased by any of the
interventions (all P = .2).
Pulse pressure (PP) was decreased by Active Beet+GFJ vs Active
Beet+H2O (P = .0003), with the peak mean difference in PP seen at
T = 2.5 hours: −4.2 mmHg (95% CI −0.3 to −8.2); see Figure 4C.
F IGURE 1 The effect of grapefruit juice
(GFJ) and beetroot juice (given at T = 0 h) on
plasma [nitrate] and [nitrite]. (A) Plasma [nitrate],
n = 11, (note: Not measured for the Placebo
Beet+GFJ intervention) (B) Plasma [nitrite]
n = 11 for Active Beet+GFJ and Active Beet
+H2O, n = 9 for Placebo Beet+GFJ. Data shown
as mean ± standard error of the mean. Statistical
significance shown as, ††P < .01, ††††P < .0001
as analysed by 2-way ANOVA between the
curves
4 O'GALLAGHER ET AL.
Active Beet+GFJ decreased PP vs Placebo Beet+GFJ (P < .0001), with
a peak mean difference in PP seen at T = 4 hours: −6.6 mmHg (95%
CI −2.0 to −11.2). Similarly, Active Beet+H2O decreased PP vs
Placebo Beet+GFJ (P = .006), with a peak mean difference in PP seen
at T = 6 hours: −4.2 mmHg (95% CI −0.4 to −8.0).
Relative to baseline, PP was decreased by the active nitrate-
containing beetroot juice combinations: Active Beet+GFJ (P = .04)
and Active Beet+H2O (both P = .03).
Mean arterial pressure (MAP, calculated as DBP + 0.4 × PP) was
not significantly changed by Active Beet+GFJ vs either Active Beet
+H2O (P = .6) or vs Placebo Beet+GFJ (P = .7; data not shown).
Relative to baseline, MAP was significantly decreased by Active Beet
+GFJ (P = .04), but not by Active Beet+H2O (P = .1) or Placebo Beet
+GFJ (P = .3; data not shown).
PP index (PPi, the ratio of the pulse pressure to MAP20) was
significantly decreased by Active Beet+GFJ vs both Active Beet+H2O
(P = .001) and Placebo Beet+GFJ (P < .0001). Active Beet+H2O
decreased PPi vs Placebo Beet+GFJ (P = .01). Relative to baseline,
PPi was decreased by Active Beet+GFJ (P = .03) and Active Beet
+H2O (P = .01) and increased by Placebo Beet+GFJ (P = .01).
3.4 | Heart rate
The addition of grapefruit juice to Active beetroot juice resulted in a
higher heart rate: Active Beet+GFJ vs Active Beet+H2O (P = .0009),
but without any significant change at individual timepoints (Figure 5).
Both Active Beet+GFJ and Active Beet+H2O increased heart rate
compared to Placebo Beet+GFJ (P < .0001 and P = .0006
F IGURE 2 The effect of grapefruit juice
(GFJ) and beetroot juice (given at T = 0 h) on
salivary nitrate secretion and metabolism.
(A) Total salivary nitrate secretion (i.e. amount of
salivary nitrate and amount of salivary nitrite),
n = 9. Data shown as mean ± standard error of
the mean. (B) Salivary nitrite production, n = 11.
Data shown as median ± interquartile range.
(C) Saliva [nitrate]:[nitrite] ratio, n = 9. Data
shown as mean ± standard error of the mean.
Statistical significance shown as †P < .05,
††P < .01 as analysed by 2-way ANOVA
between the curves (Placebo Beet+GFJ data not
presented)
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respectively). Relative to baseline, heart rate was decreased by
Active Beet+H2O (P = .03) and Placebo Beet+GFJ (P = .03), but not by
Active Beet+GFJ (P = .09).
3.5 | Urine
Grapefruit juice as Placebo Beet+GFJ increased urinary pH vs Active
Beet+H2O (P < .0003) but not vs Active Beet+GFJ (P = .1; Figure 6).
3.6 | Taste score
The addition of grapefruit juice to active beetroot juice resulted in a
significantly higher taste score, suggesting a greater palatability
compared to beetroot juice and water: Active Beet+GFJ vs Active
Beet+H2O: +1.4 (95% CI 0.15 to 2.58), P = .03, and Placebo Beet+GFJ
vs Active Beet+H2O: +1.56 (95% CI 0.16 to 2.95), P = .03. There
was no significant difference in taste score between the 2 grapefruit
juice-containing interventions (P = .7; Figure 7).
4 | DISCUSSION
We have demonstrated that co-ingestion of grapefruit juice with
dietary nitrate results in a potentiation of dietary nitrate's effect in
lowering SBP and PP, albeit without the hypothesised increase in
plasma [nitrite]. Therefore, the effect on SBP was unlikely to have
been via furanocoumarin-mediated CYP3A4 inhibition of nitrite
oxidation. Indeed, plasma [nitrite] was lower with Active Beet+GFJ
compared to the Active Beet+H2O (though DBP was slightly higher
with Active Beet+GFJ vs Active Beet+H2O).
The potential mechanism(s) by which grapefruit juice (in the
Beet+GFJ intervention) decreases plasma [nitrite] vs Beet+H2O
will be considered by the kinetic processes (absorption, distribution,
metabolism and secretion/excretion) at different anatomical sites.
In the oral cavity, grapefruit juice appears to have inhibited the
metabolic conversion of nitrate to nitrite, as indicated by the
increased salivary [nitrate]:[nitrite] ratio. This was associated with an
unexpected increase in salivary pH with grapefruit juice. Whilst
previous studies have suggested the relationship between salivary pH
F IGURE 3 The effect of grapefruit juice
(GFJ) and beetroot juice (given at T = 0 h) on
saliva volume and pH. (A) Salivary volume,
n = 11 for active beet+GFJ and active beet H2O,
n = 9 for Placebo Beet+GFJ. (B) Salivary pH
values, n = 11 for Active Beet+GFJ and Active
Beet+H2O, n = 7 for Placebo Beet+GFJ. Data
shown as mean ± standard error of the mean.
Statistical significance shown as, †P < .05,
††P < .01, ††††P < .0001 as analysed by 2-way
ANOVA between the curves
TABLE 2 Baseline blood pressure (BP) parameters (taken as an







SBP (mmHg) 108.1 ± 7.5 107.7 ± 8.2 106.5 ± 8.7
DBP (mmHg) 67.6 ± 5.6 66.2 ± 6.2 67.2 ± 6.1
MAP (mmHg) 83.8 ± 6.1 82.8 ± 6.2 83.0 ± 6.9
PP (mmHg) 40.5 ± 4.0 41.5 ± 7.0 39.3 ± 4.8
PPi 0.48 ± 0.04 0.50 ± 0.09 0.47 ± 0.05
GFJ, grapefruit juice; SBP, systolic BP; DBP, diastolic BP; MAP, mean
arterial pressure; PP, pulse pressure; PPi, pulse pressure index. Data are
mean ± standard deviation
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F IGURE 4 The effect of grapefruit juice
(GFJ) and beetroot juice (given at T = 0 h) on
blood pressure (BP). (A) Systolic BP. (B) Diastolic
BP. (C) Pulse pressure. n = 9 for all interventions
and parameters assessed. Statistical significance
shown as †P < .05, ††P < .01, †††P < .001, ††††
P < .0001 as analysed by 2-way ANOVA
between the curves and #P < .05, ##P < .01 by
1-way ANOVA vs baseline
F IGURE 5 The effect of grapefruit
juice (GFJ) and beetroot juice (given at
T = 0 h) on heart rate. n = 9 for all
interventions and parameters assessed.
Statistical significance shown as
†††P < .001, †††† P < .0001 as analysed by
2-way ANOVA between the curves and
#P < .05 by 1-way ANOVA vs baseline
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and nitrate reduction is in the opposite direction,21,22 these are
models, or only checked at a single timepoint of 30 minutes,
rather than full physiological/kinetic studies. Our finding requires
confirmation in further detailed mechanistic studies.
A potential additional contributing factor is the lower total
salivary volume with grapefruit juice. Whilst the astringent effect of
grapefruit (juice) may account for the absolute decrease in the total
salivary nitrate secretion (measured as the total amount of salivary
nitrate and nitrite: a secretory/excretory kinetic mechanism), this
would not account for the change in rate of conversion of nitrate to
nitrite (a metabolic mechanism) as indicated by the relative salivary
[nitrate]:[nitrite] ratio. It is therefore likely that both kinetic
processes—decreased metabolism and secretion—contribute to the
decreased absolute salivary nitrite production.
Grapefruit juice per se decreased salivary pH (Placebo Beet+GFJ)
from baseline and compared to the other 2 interventions. Dietary nitrate
tended to increase salivary pH, which has been reported previously23
and in combination with grapefruit juice resulted in a further increase in
salivary pH. The mechanism for this interaction is not currently clear,
although it could relate to carbonic anhydrase: quercetin, a flavonol
found in grapefruit juice, has been demonstrated to inhibit human
carbonic anhydrase in vitro.24 Grapefruit juice also acted to increase
the urinary pH, further supporting an effect on carbonic anhydrase.
In the stomach, grapefruit juice might impact gastric pH,
modifying the chemical reactions contributing to a lower plasma
[nitrite]. Despite being a citrus fruit, ingestion of a similar volume of
grapefruit juice as our study (180 mL) has been found to more than
double gastric pH (from 1.39 ± 0.4 to 3.20 ± 0.3; P < .05), albeit in the
presence of indinavir.25 Nitrite is reduced to NO and other NO
species by acid disproportionation (with the remaining nitrite being
absorbed into the systemic circulation) in the stomach: accordingly
gastric NO production is inhibited by proton-pump inhibitors.10 In
rats, increasing gastric pH with a proton-pump inhibitor diminished
the BP-lowering effect of orally-ingested nitrite independently of
plasma [nitrite].26 Similar results with a dissociation between plasma
[nitrite] and BP following proton-pump inhibitor administration have
been found in the study by Montenegro and colleagues in humans.27
In their study, the plasma [nitrite] at 60 min following oral sodium
nitrite ingestion, was significantly greater with the proton-pump
inhibitor esomeprazole compared to placebo. However, the nitrite-
induced BP decrease with placebo was blocked by esomeprazole.
Therefore, the relationship between plasma nitrite and BP was
comparable to our data. These data have important implications:
stomach pH appears to be an important modulator of the
enterosalivary pathway. However, dietary nitrate's BP-lowering effect
is not fully explained by an increase in plasma [nitrite] alone. Such
uncoupling of the plasma [nitrite] from the clinical response suggests
that other NO species may be involved which were not measured in
this study e.g. thiocyanates in beetroot juice interacting to form
S-nitrosothiols (increasing gastric pH with esomeprazole did not
decrease S-nitrosothiol levels in the study of Montenegro et al.27).
Altered gastric NO species may also have an effect on splanchnic
blood flow, which may in turn impact systemic BP.
F IGURE 6 The effect of grapefruit juice
(GFJ) and beetroot juice (given at T = 0 h) on
urinary pH, n = 11 for Active Beet+GFJ and
Active Beet+H2O, n = 9 for Placebo Beet
+GFJ. Statistical significance shown as
†††P < .001 as analysed by 2-way ANOVA
between the curves
F IGURE 7 Taste challenge: Mean taste scores for each cocktail
containing grapefruit (GFJ) and/or beetroot juice, n = 11 for Active
Beet+GFJ and Active Beet+H2O, n = 9 for Placebo Beet+GFJ. Data
expressed as mean ± standard error of the mean. Statistical
significance shown as *P < .05
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This study was designed to assess the effect of grapefruit juice,
with the mechanism postulated to be mediated by furanocoumarins in
the juice. However, grapefruit juice also contains a number of other
substances that may play a role through mechanisms other than
CYP3A4. For example, grapefruit juice is abundant in compounds
which inhibit organic anion-transporting peptide28 and therefore
potentially inhibits the uptake of organic anions; whether absorption
of inorganic ions (such as nitrite) would be affected is not known. In
addition to organic anion-transporting peptide, p-glycoprotein
represents another possible mechanism by which grapefruit juice may
affect gut absorption.29
Grapefruit juice also contains reducing agents, such as ascorbic
acid, which could reduce nitrite to NO in the gut, diminishing nitrite
absorption into the plasma (however the preparation of beetroot juice
used also contains 2% lemon juice, which itself will contain ascorbic
acid). Other potential reducing agents found in grapefruit juice are
flavonoids, naringin, kaempferol and quercetin. In the stomach, nitrite
and quercetin react to form NO,30,31 a process that is favoured by
acidic conditions. Whilst, the short half-life of NO would suggest that
NO produced in the stomach would have only direct local effects, this
has the potential to indirectly affect systemic BP via splanchnic blood
flow as suggested above. Currently there is no evidence of flavonols
reducing nitrite systemically.
The enhanced SBP-lowering effects of dietary nitrate and
grapefruit juice co-consumption could represent a synergistic dynamic
effect. Placebo Beet+GFJ was associated with a trend to decrease
SBP (P = .09). It is therefore possible that grapefruit juice has its own
independent BP-lowering effect; however, this study was not
designed to measure such an effect. Combining the BP-lowering
effect of beetroot juice with grapefruit juice would therefore be
expected to result in an enhanced BP-lowering effect compared to
beetroot juice alone. Indeed, grapefruit juice contains several
vasoactive compounds including naringin and quercetin.32 Naringin,
when given daily for 6 weeks as grapefruit juice, has been shown to
have a beneficial effect on arterial stiffness compared to treatment
with a naringin-free grapefruit juice control,33 and a single dose of
quercetin has been shown to increase brachial artery diameter.34
Actions of these vasoactive compounds might therefore explain the
decreased PP observed for Active Beet+GFJ vs Active Beet+H2O.
The results of this study have interesting potential clinical
implications. The combination of beetroot juice with grapefruit juice
decreased SBP and had a small but significant effect on increasing
DBP. Therefore, the combination of the juices reduced PP (and PPi) but
not MAP. Raised PP is highly prognostic for adverse cardiovascular
events.35 Furthermore, given the adverse effect of a low DBP in
patients with isolated systolic hypertension,36 an intervention which
decreases SBP without affecting DBP has potential clinical utility.
5 | LIMITATIONS
This study had several limitations. This was a pilot study, involving a
small number of participants, who were healthy volunteers. Larger
studies of longer duration are required to confirm the findings
reported in this paper and their applicability to patients with
hypertension. In addition, in this study only the volunteers were
blinded (to the Active vs Placebo Beet juice cocktails), therefore
introducing the risk of bias. Future studies should be double-blinded
to reduce this risk.
In this study BP was measured as peripheral BP. Given that
inorganic nitrite is known to be an arterial dilator with selectivity for
medium and large arteries over smaller resistance arterioles37,38 the
effects on central BP may have been more marked than those on
peripheral BP37 (as seen in the VaSera study, where 6 months
treatments with beetroot juice was shown to decrease central,
but not peripheral BP in hypertensive patients with/at risk of type
2 diabetes39,40). It would therefore have been preferable to have
recorded measures of central BP in addition to peripheral BP.
A further limitation of the study design is that both juices
contain bioactive substances other than those being studied,
including ascorbic acid and flavonoids in the grapefruit juice, and
thiocyanates in the beetroot juice, therefore limiting the study's
ability to describe mechanistic aspects of the enterosalivary
circulation over and above the clinical end-point of BP decrease as
a result of combining the 2 juices. Paradoxically, although the
complex mix of bioactive juices is a limitation, so too is the
simplicity of this study as it is unclear whether the clinical effects
seen in this tightly controlled study are reproducible when added to
a standard, mixed diet.
6 | CONCLUSION
In summary, our study found that grapefruit juice potentiated the
SBP-lowering effect of beetroot juice, despite a decrease in plasma
[nitrite]. Grapefruit juice appears to have inhibited the metabolic
conversion of nitrate to nitrite, as indicated by the increased salivary
[nitrate]:[nitrite], associated with an increase in salivary pH with
grapefruit juice. The BP-lowering effect may have been due to other
NO species not measured in this study, such as S-nitrosothiols.
These findings have implications for maximising the clinical benefit of
dietary nitrate and also in further exploring mechanisms of dietary
nitrate bioactivation. Given that the taste was improved by grapefruit
juice, this combination has potential for use as a dietary approach to
improve BP.
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